Taigen Biopharmaceuticals Holdings (4157) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 太景*-KY

Taigen Biopharmaceuticals Holdings (4157) reported revenue of NT$5.2 million for Oct 2026, +60.2% year on year and +66.6% from the previous month. Revenue for Jan–Oct 2026 was NT$37 million (+17.2% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 138 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$3.9 million24/10Nov 2024 NT$3.2 millionDec 2024 NT$3.4 millionJan 2025 NT$4.2 millionFeb 2025 NT$3.4 million25/02Mar 2025 NT$3.3 millionApr 2025 NT$3.7 millionMay 2025 NT$3.8 millionJun 2025 NT$3.3 million25/06Jul 2025 NT$3.1 millionAug 2025 NT$2.6 millionSep 2025 NT$1 millionOct 2025 NT$3.3 million25/10Nov 2025 NT$4.1 millionDec 2025 NT$223.8 millionJan 2026 NT$6 millionFeb 2026 NT$2.9 million26/02Mar 2026 NT$1.4 millionApr 2026 NT$2.3 millionMay 2026 NT$2.9 millionJun 2026 NT$3 million26/06Jul 2026 NT$3 millionAug 2026 NT$7.1 millionSep 2026 NT$3.2 millionOct 2026 NT$5.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$5.2 million+60.2%+66.6%
Sep 2026NT$3.2 million+212.8%-55.3%
Aug 2026NT$7.1 million+172.2%+138.6%
Jul 2026NT$3 million-4.0%-2.2%
Jun 2026NT$3 million-7.1%+3.4%
May 2026NT$2.9 million-22.7%+28.2%
Apr 2026NT$2.3 million-37.8%+57.6%
Mar 2026NT$1.4 million-55.9%-49.3%
Feb 2026NT$2.9 million-15.5%-52.7%
Jan 2026NT$6 million+43.0%-97.3%
Dec 2025NT$223.8 million+6,482.8%+5,327.1%
Nov 2025NT$4.1 million+30.8%+25.8%
Oct 2025NT$3.3 million-16.7%+225.4%
Sep 2025NT$1 million-66.5%-61.1%
Aug 2025NT$2.6 million-17.1%-15.8%
Jul 2025NT$3.1 million+24.0%-5.4%
Jun 2025NT$3.3 million+51.9%-14.0%
May 2025NT$3.8 million-96.7%+3.3%
Apr 2025NT$3.7 million-24.0%+11.7%
Mar 2025NT$3.3 million+27.0%-2.9%
Feb 2025NT$3.4 million+34.5%-20.1%
Jan 2025NT$4.2 million-13.8%+24.2%
Dec 2024NT$3.4 million+15.8%+7.8%
Nov 2024NT$3.2 million+1.4%-19.8%
Oct 2024NT$3.9 million+54.5%+31.1%

Jan–Oct 2026 cumulative: NT$37 million (+17.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Taigen Biopharmaceuticals Holdings vs PEC / Taigen Biopharmaceuticals Holdings vs Lotus Pharm / Taigen Biopharmaceuticals Holdings vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本月營收較去年同期增加,主要係因認列奈諾沙星授權至越南之里程碑款收入所致

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16